These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 26054881)

  • 1. Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease.
    Yoritaka A; Kawajiri S; Yamamoto Y; Nakahara T; Ando M; Hashimoto K; Nagase M; Saito Y; Hattori N
    Parkinsonism Relat Disord; 2015 Aug; 21(8):911-6. PubMed ID: 26054881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.
    ; Beal MF; Oakes D; Shoulson I; Henchcliffe C; Galpern WR; Haas R; Juncos JL; Nutt JG; Voss TS; Ravina B; Shults CM; Helles K; Snively V; Lew MF; Griebner B; Watts A; Gao S; Pourcher E; Bond L; Kompoliti K; Agarwal P; Sia C; Jog M; Cole L; Sultana M; Kurlan R; Richard I; Deeley C; Waters CH; Figueroa A; Arkun A; Brodsky M; Ondo WG; Hunter CB; Jimenez-Shahed J; Palao A; Miyasaki JM; So J; Tetrud J; Reys L; Smith K; Singer C; Blenke A; Russell DS; Cotto C; Friedman JH; Lannon M; Zhang L; Drasby E; Kumar R; Subramanian T; Ford DS; Grimes DA; Cote D; Conway J; Siderowf AD; Evatt ML; Sommerfeld B; Lieberman AN; Okun MS; Rodriguez RL; Merritt S; Swartz CL; Martin WR; King P; Stover N; Guthrie S; Watts RL; Ahmed A; Fernandez HH; Winters A; Mari Z; Dawson TM; Dunlop B; Feigin AS; Shannon B; Nirenberg MJ; Ogg M; Ellias SA; Thomas CA; Frei K; Bodis-Wollner I; Glazman S; Mayer T; Hauser RA; Pahwa R; Langhammer A; Ranawaya R; Derwent L; Sethi KD; Farrow B; Prakash R; Litvan I; Robinson A; Sahay A; Gartner M; Hinson VK; Markind S; Pelikan M; Perlmutter JS; Hartlein J; Molho E; Evans S; Adler CH; Duffy A; Lind M; Elmer L; Davis K; Spears J; Wilson S; Leehey MA; Hermanowicz N; Niswonger S; Shill HA; Obradov S; Rajput A; Cowper M; Lessig S; Song D; Fontaine D; Zadikoff C; Williams K; Blindauer KA; Bergholte J; Propsom CS; Stacy MA; Field J; Mihaila D; Chilton M; Uc EY; Sieren J; Simon DK; Kraics L; Silver A; Boyd JT; Hamill RW; Ingvoldstad C; Young J; Thomas K; Kostyk SK; Wojcieszek J; Pfeiffer RF; Panisset M; Beland M; Reich SG; Cines M; Zappala N; Rivest J; Zweig R; Lumina LP; Hilliard CL; Grill S; Kellermann M; Tuite P; Rolandelli S; Kang UJ; Young J; Rao J; Cook MM; Severt L; Boyar K
    JAMA Neurol; 2014 May; 71(5):543-52. PubMed ID: 24664227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A; Jost WH; Vieregge P; Spiegel J; Greulich W; Durner J; Müller T; Kupsch A; Henningsen H; Oertel WH; Fuchs G; Kuhn W; Niklowitz P; Koch R; Herting B; Reichmann H;
    Arch Neurol; 2007 Jul; 64(7):938-44. PubMed ID: 17502459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials.
    Zhu ZG; Sun MX; Zhang WL; Wang WW; Jin YM; Xie CL
    Neurol Sci; 2017 Feb; 38(2):215-224. PubMed ID: 27830343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
    Shults CW; Oakes D; Kieburtz K; Beal MF; Haas R; Plumb S; Juncos JL; Nutt J; Shoulson I; Carter J; Kompoliti K; Perlmutter JS; Reich S; Stern M; Watts RL; Kurlan R; Molho E; Harrison M; Lew M;
    Arch Neurol; 2002 Oct; 59(10):1541-50. PubMed ID: 12374491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial.
    Donnino MW; Mortensen SJ; Andersen LW; Chase M; Berg KM; Balkema J; Radhakrishnan J; Gazmuri RJ; Liu X; Cocchi MN
    Crit Care; 2015 Jul; 19(1):275. PubMed ID: 26130237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease?
    Seet RC; Lim EC; Tan JJ; Quek AM; Chow AW; Chong WL; Ng MP; Ong CN; Halliwell B
    Antioxid Redox Signal; 2014 Jul; 21(2):211-7. PubMed ID: 24410614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
    Yoritaka A; Takanashi M; Hirayama M; Nakahara T; Ohta S; Hattori N
    Mov Disord; 2013 Jun; 28(6):836-9. PubMed ID: 23400965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Coenzyme Q10 in Parkinson's disease. Symptomatic or neuroprotective effects?].
    Storch A
    Nervenarzt; 2007 Dec; 78(12):1378-82. PubMed ID: 17508194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Negida A; Menshawy A; El Ashal G; Elfouly Y; Hani Y; Hegazy Y; El Ghonimy S; Fouda S; Rashad Y
    CNS Neurol Disord Drug Targets; 2016; 15(1):45-53. PubMed ID: 26553164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coenzyme Q10 for Parkinson's disease.
    Liu J; Wang L; Zhan SY; Xia Y
    Cochrane Database Syst Rev; 2011 Dec; (12):CD008150. PubMed ID: 22161420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquinol is superior to ubiquinone to enhance Coenzyme Q10 status in older men.
    Zhang Y; Liu J; Chen XQ; Oliver Chen CY
    Food Funct; 2018 Nov; 9(11):5653-5659. PubMed ID: 30302465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
    Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
    Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
    Fénelon G; Giménez-Roldán S; Montastruc JL; Bermejo F; Durif F; Bourdeix I; Péré JJ; Galiano L; Schadrack J
    J Neural Transm (Vienna); 2003 Mar; 110(3):239-51. PubMed ID: 12658373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
    Smith KM; Eyal E; Weintraub D;
    JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A multi-centered randomized double-blinded controlled clinical study on efficacy of gulling pa'an capsule in treating Parkinson's disease].
    Zhao GH; Meng QG; Yu XD
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jul; 29(7):590-4. PubMed ID: 19852288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WITHDRAWN: Coenzyme Q10 for Parkinson's disease.
    Liu J; Wang LN; Zhan SY; Xia Y
    Cochrane Database Syst Rev; 2012 May; 2012(5):CD008150. PubMed ID: 22592726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.